January 3, 2023 01:03 PM EST

IRA's inflation-linked rebates would've saved government $3.7B from 2018 to 2020 — JAMA research

Paul Schloesser

Associate Editor

A new analysis from Harvard’s Aaron Kesselheim points to the recently signed Inflation Reduction Act as a way that Medicare could’ve saved even more money …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

IRA's inflation-linked rebates would've saved government $3.7B from 2018 to 2020 — JAMA research

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Sanofi introduces new 340B payment model — report

Are programs with compounded GLP-1s safe for your population?

IRA's in­fla­tion-linked re­bates would've saved gov­ern­ment $3.7B from 2018 to 2020 — JA­MA re­search

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

IRA's inflation-linked rebates would've saved government $3.7B from 2018 to 2020 — JAMA research

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Sanofi introduces new 340B payment model — report

Are programs with compounded GLP-1s safe for your population?